Results 171 to 180 of about 29,491 (205)
Some of the next articles are maybe not open access.
Radionuclides and carrier molecules for therapy
Physics in Medicine and Biology, 1996Although radionuclide therapy has been around for a long time, this modality of cancer treatment has been limited mainly to the use of [32P]-phosphate and [131I]-sodium iodide. The last few years, however, have seen an increased interest in this area due to new developments of radionuclides and carrier molecules that may provide selective targeting of ...
openaire +2 more sources
Radionuclide therapy beyond radioiodine
Wiener Medizinische Wochenschrift, 2012For decades, Iodine-131 has been used for the treatment of patients with thyroid cancer. In recent years, increasingly, other radiopharmaceuticals are in clinical use in the treatment of various malignant diseases. Although in principle these therapies-as in all applications of radionuclides-special radiation protection measures are required, a ...
openaire +2 more sources
Beta-Emitting Radionuclides for Peptide Receptor Radionuclide Therapy
Current Topics in Medicinal Chemistry, 2013The paper focuses on the β-emitting radionuclides which might be useful for peptide receptor radionuclide therapy, PRRT. For the effective design of the radiopharmaceutical, the choice of radionuclide will depend on the purpose for which the radioligand is being used and on the physicochemical properties of the radionuclide.
J L, Parus, R, Mikolajczak
openaire +2 more sources
Radionuclide therapy of hematologic disorders
Seminars in Nuclear Medicine, 197932P is effective therapy for polycythemia and primary thrombocytosis. The Polycythemia Vera Study Group is comparing radioactive phosphorus with alkylating agents to determine relative efficacy. Less well investigated is the effectiveness of 32P vs. busulfan in chronic granulocytic leukemia. Endolymphatic administration of radiopharmaceuticals may play
openaire +2 more sources
Targeted Radionuclide Therapy in Glioblastoma
ACS Applied Materials & InterfacesDespite the development of various novel therapies, glioblastoma (GBM) remains a devastating disease, with a median survival of less than 15 months. Recently, targeted radionuclide therapy has shown significant progress in treating solid tumors, with the approval of Lutathera for neuroendocrine tumors and Pluvicto for prostate cancer by the US Food and
Xiaobin Zhao +7 more
openaire +2 more sources
Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications
Pharmaceutics, 2021Frank Wuest, Jan Andersson
exaly
Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
Advanced Drug Delivery Reviews, 2022Guanglin Wang, Mingyuan Gao, Hu Kuan
exaly
Clinical Advances and Perspectives in Targeted Radionuclide Therapy
Pharmaceutics, 2023Nicolas Lepareur +2 more
exaly